Patients with HR-MDS and AML, characterized by a baseline frequency of ≤29% CD57+CXCR3+CD8+ T cells, demonstrated higher rates of response to AZA (Fig. 3G). This evidence concerns the gene B3GAT1 and acute myeloid leukemia.